tbuckley/cabot-search huggingface dataset:
In vitro activation of CMV-specific T-cell response using CyaA toxoids delivering peptide antigenic epitopes derived from pp65 protein.
Authors: J. Jelinek, I. Adkins, P. Sebo, J. Michalek
Journal: Journal of Clinical Oncology (2010)

6610 Background: Human cytomegalovirus (CMV) infects between 50%-85% of adults and can cause life-threatening infections in immunocompromised patients (e.c. recipients of allogeneic hematopoietic stem cells or solid organ transplants). Therefore, peptide vaccination is being developed as a promising immunotherapeutic approach for treatment of patients at risk of CMV-disease. The enzymatically inactive toxoid of Bordetella adenylate cyclase (CyaA) was shown to be an efficient tool for delivery of peptide epitopes and stimulation of antigen-specific T cell immune responses. Methods: In this study, we investigated the capacity of two CyaA constructs to deliver epitopes from the CMV phosphoprotein pp65 to activate T cells of CMV-seropositive and CMV-seronegative healthy donors in vitro. Immune response of T cells was monitored using Flow cytometry and Cytometric Beads Array. Results: Expansion of CMV-specific T cells secreting g-interferon as well as increase of total IFN-g and TNF-α production could be detected after in vitro stimulation with CyaA-CMV constructs, while limited activation of T cells occurred with free peptides. No immune response was evoked by control CyaA without CMV antigenic peptides. Conclusions: These data reveal the potential of CyaA constructs as a tool for fast and reliable detection of CMV-specific immunity and for immunoprophylactic, as well as immunotherapeutic application against CMV-associated diseases in immunocompromised patients. This study was supported by grants MSMT NPVII 2B06058 and IGA MZCR NS9871. No significant financial relationships to disclose.
Improvement of vascular function by magnetic nanoparticle-assisted circumferential gene transfer into the native endothelium
Authors: Sarah Vosen, Sarah Rieck, Alexandra Heidsieck, Olga Mykhaylyk, Katrin Zimmermann, Christian Plank, Bernhard Gleich, Alexander Pfeifer, Bernd K. Fleischmann, Daniela Wenzel
Journal: Journal of Controlled Release (2016)
Spinal column chordoma: prognostic significance of clinical variables and<i>T (brachyury</i>) gene SNP rs2305089 for local recurrence and overall survival
Authors: Chetan Bettegowda, Stephen Yip, Sheng-Fu Larry Lo, Charles G. Fisher, Stefano Boriani, Laurence D. Rhines, Joanna Y. Wang, Aron Lazary, Marco Gambarotti, Wei-Lien Wang, Alessandro Luzzati, Mark B. Dekutoski, Mark H. Bilsky, Dean Chou, Michael G. Fehlings, Edward F. McCarthy, Nasir A. Quraishi, Jeremy J. Reynolds, Daniel M. Sciubba, Richard P. Williams, Jean-Paul Wolinsky, Patricia L. Zadnik, Ming Zhang, Niccole M. Germscheid, Vasiliki Kalampoki, Peter Pal Varga, Ziya L. Gokaslan
Journal: Neuro-Oncology (2016)

Chordomas are rare, locally aggressive bony tumors associated with poor outcomes. Recently, the single nucleotide polymorphism (SNP) rs2305089 in the T (brachyury) gene was strongly associated with sporadic chordoma development, but its clinical utility is undetermined. In 333 patients with spinal chordomas, we identified prognostic factors for local recurrence-free survival (LRFS) and overall survival and assessed the prognostic significance of the rs2305089 SNP. The median LRFS was 5.2 years from the time of surgery (95% CI: 3.8–6.0); greater tumor volume (≥100cm3) (hazard ratio [HR] = 1.99, 95% CI: 1.26–3.15, P = .003) and Enneking inappropriate resections (HR = 2.35, 95% CI: 1.37–4.03, P = .002) were independent predictors of LRFS. The median overall survival was 7.0 years (95% CI: 5.8–8.4), and was associated with older age at surgery (HR = 1.11 per 5-year increase, 95% CI: 1.02–1.21, P = .012) and previous surgical resection (HR = 1.73, 95% CI: 1.03–2.89, P = .038). One hundred two of 109 patients (93.6%) with available pathologic specimens harbored the A variant at rs2305089; these patients had significantly improved survival compared with those lacking the variant (P = .001), but there was no association between SNP status and LRFS (P = .876). The ability to achieve a wide en bloc resection at the time of the primary surgery is a critical preoperative consideration, as subtotal resections likely complicate later management. This is the first time the rs2305089 SNP has been implicated in the prognosis of individuals with chordoma, suggesting that screening all patients may be instructive for risk stratification.
BCL-2 system analysis identifies high-risk colorectal cancer patients
Authors: Andreas U Lindner, Manuela Salvucci, Clare Morgan, Naser Monsefi, Alexa J Resler, Mattia Cremona, Sarah Curry, Sinead Toomey, Robert O'Byrne, Orna Bacon, Michael Stühler, Lorna Flanagan, Richard Wilson, Patrick G Johnston, Manuel Salto-Tellez, Sophie Camilleri-Broët, Deborah A McNamara, Elaine W Kay, Bryan T Hennessy, Pierre Laurent-Puig, Sandra Van Schaeybroeck, Jochen H M Prehn
Journal: Gut (2016)

The mitochondrial apoptosis pathway is controlled by an interaction of multiple BCL-2 family proteins, and plays a key role in tumour progression and therapy responses. We assessed the prognostic potential of an experimentally validated, mathematical model of BCL-2 protein interactions (DR_MOMP) in patients with stage III colorectal cancer (CRC).
Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Authors: Jing Liu, Stephen J. Blake, Michelle C.R. Yong, Heidi Harjunpää, Shin Foong Ngiow, Kazuyoshi Takeda, Arabella Young, Jake S. O'Donnell, Stacey Allen, Mark J. Smyth, Michele W.L. Teng
Journal: Cancer Discovery (2016)

Abstract Immunotherapy has recently entered a renaissance phase with the approval of multiple agents for the treatment of cancer. Immunotherapy stands ready to join traditional modalities, including surgery, chemotherapy, radiation, and hormone therapy, as a pillar of cancer treatment. Although immunotherapy has begun to have success in advanced cancer treatment, its scheduling and efficacy with surgery to treat earlier stages of cancer and prevent distant metastases have not been systematically examined. Here, we have used two models of spontaneously metastatic breast cancers in mice to illustrate the significantly greater therapeutic power of neoadjuvant, compared with adjuvant, immunotherapies in the context of primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. These data now provide a strong rationale to extensively test and compare neoadjuvant immunotherapy in humans. Significance: We demonstrate the significantly greater therapeutic efficacy of neoadjuvant, compared with adjuvant, immunotherapies to eradicate distant metastases following primary tumor resection. Elevated and sustained peripheral tumor-specific immune responses underpinned the outcome, and blood sampling of tumor-specific CD8+ T cells immediately prior to and post surgery may provide a predictor of outcome. Cancer Discov; 6(12); 1382–99. ©2016 AACR. See related commentary by Melero et al., p. 1312. This article is highlighted in the In This Issue feature, p. 1293
Azacitidine in Acute Myeloid Leukemia: Comparison of Patients with AML-MRF Vs AML-NOS Enrolled in the Austrian Azacitidine Registry
Authors: Lisa Pleyer, Sonja Burgstaller, Reinhard Stauder, Michael Girschikofsky, Werner Linkesch, Michael Pfeilstöcker, Eva Maria Autzinger, Christoph Tinchon, Thamer Sliwa, Alois Lang, Wolfgang R. Sperr, Dietmar Geissler, Peter Krippl, Daniela Voskova, Dieter H. Rossmann, Konstantin Schlick, Josef Thaler, Britta Halter, Sigrid Machherndl-Spandl, Georg Theiler, Peter Valent, Otto Eckmüllner, Richard Greil
Journal: Blood (2014)
Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study
Authors: K. Ridwelski, J. Fahlke, E. Kettner, C. Schmidt, U. Keilholz, D. Quietzsch, M. Assmann, M. Stauch, K. Zierau, H. Lippert
Journal: Journal of Clinical Oncology (2008)

4512 Background: Based on promising phase II studies, this randomized, multicenter phase III study compared DC with a commonly used regimen, FLC. Methods: Patients (pts) aged 18–75 years with stage III (T4, nonresectable) or IV gastric cancer, Karnofsky performance status (KPS) ≥60%, and life expectancy ≥3 months were randomized to receive ≤6 cycles of DC (D 75 mg/m² and C 75 mg/m²; both as 1-h infusions d1q3w) or ≤4 cycles of FLC (5-FU 2,000 mg/m² [24-h infusion] and L 500 mg/m² [2-h infusion], both d1, 8, 15, 22, 29, 36 q7w, plus C 50 mg/m² [1-h infusion], d1, 15, 29 q7w). C was omitted in FLC Cycle 4. Treatment was stopped in the event of disease progression, intolerable toxicity, or consent withdrawal. Tumors were staged on D 40, 85, 135, and 190. The study endpoints were time to progression (primary) and toxicity, response rate, quality of life, and overall survival (secondary). Results: At 12 months’ follow-up, of 273 randomly assigned pts preliminary data are available for 235 pts (DC: 112, FLC: 123; median age 62 [range: 32–74] years; median KPS 80% [range: 60–100%]. Baseline characteristics were similar in both arms. Median cycles administered were 5 (DC) and 2 (FLC). The ORR (PR+CR) was 29.5% for DC and 29,3% for FLC. Median time to progression was 6.3 months (DC) and 6.6 months (FLC). Median overall survival time was 9.4 months for DC and 10.2 months for FLC. The most relevant grade 3 and 4 events per patient included neutropenia (DC = 41.1%; FLC = 12.2%) and GI (DC: 19.6%; FLC: 28.5%). Conclusions: Both regimens were active. No significant differences in the examined parameters were observed. DC was well tolerated with a predictable toxicity profile. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Merck, Roche, sanofi-aventis
Decay of Ccc-Dna is Slow and Marks Persistence of Intrahepatic Viral Dna Synthesis during Long-Term Tenofovir Treatment in Hiv-Hbv Co-Infected Patients
Authors: A. Boyd, K. Lacombe, F. Lavocat, P. Miailhes, C. Lascoux-Combe, P.-M. Girard, F. Zoulim
Journal: Journal of Hepatology (2016)
Switching Tenofovir Disoproxil Fumarate (TDF) plus Entecavir Combination Therapy to TDF Monotherapy is Safe and Efficacious in Patients with Multiple Drug-resistant Chronic Hepatitis B: Randomized Trial
Authors: Y.-S. Lim, B.C. Yoo, K.S. Byun, S.Y. Kwon, Y.J. Kim, J. An, H.C. Lee, Y.S. Lee
Journal: Journal of Hepatology (2016)
Case 18-1962
Authors: Gordon A. Donaldson
Journal: New England Journal of Medicine (1962)

Presentation of CaseA seventy-four-year-old man was admitted to the hospital because of abdominal pain.Crampy abdominal pain began one week previously and recurred intermittently until four days before entry, when it became constant. The pain was centered in the right upper quadrant of the abdomen, with radiation into the back, the right costovertebral angle and the base of the penis, and was associated with moderate anorexia and slight constipation. The symptoms gradually increased in severity, and on the day before admission he became feverish and noticed a momentary shift of the pain into the right lower quadrant of the . . .
A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with Hbeag-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results
Authors: M. Buti, E. Gane, W.K. Seto, H.L.Y. Chan, W.-L. Chuang, T. Stepanova, A.J. Hui, Y.-S. Lim, R. Mehta, H.L.A. Janssen, S.K. Acharya, J.F. Flaherty, B. Massetto, A. Cathcart, P. Dinh, G.M. Subramanian, J.G. McHutchison, C. Pan, M. Brunetto, N. Izumi, P. Marcellin
Journal: Journal of Hepatology (2016)
Genotypic and Phenotypic Resistance in Clinical Samples Submitted for HCV NS5B Drug Resistance Testing in the Us
Authors: J.D. Reeves, J. Volpe, K. Strommen, E. Anton, S. Martens, D. Yang, J. Whitcomb, W. Huang, C.J. Petropoulos, C. Walworth
Journal: Journal of Hepatology (2016)
NDI-010976, a Potent, Liver-Directed, Oral Inhibitor of Acetyl Coa Carboxylase for Non-Alcoholic Steatohepatitis: Pharmacodynamic Effects on Hepatic De Novo Lipogenesis in Obese but Otherwise Healthy Adult Male Volunteers
Authors: W.F. Westlin, H. Blanchette, G. Harriman, H.J. Harwood, R. Kapeller, S. Lennon, W. Miao, C. Beysen, M. Dalidd, S. Turner, K. Stiede, T. Schmalbach
Journal: Journal of Hepatology (2016)
Risk of end-stage renal disease in Japanese patients with chronic kidney disease increases proportionately to decline in estimated glomerular filtration rate
Authors: Kunihiro Matsushita, Jingsha Chen, Yingying Sang, Shoshana H. Ballew, Ryutaro Shimazaki, Masafumi Fukagawa, Enyu Imai, Josef Coresh, Akira Hishida
Journal: Kidney International (2016)
The Accuracy of the Baseline Peripheral Lymphocyte Value in Predicting Overall Survival in Hepatocellular Carcinoma Patients Treated with Sorafenib Reinforces the Impact of the Immune Response on Tumor Progression
Authors: M. Reig, A. Ribeiro, A. Gazzola, Á. Díaz, N. LLarch, G. Iserte, A. Forner, L. Boix, J.M. Lopez-Oliva, A. Darnell, J. Rimola, C. Ayuso, J. Bruix
Journal: Journal of Hepatology (2016)
Chemotherapy Plus Cetuximab in Patients with Colorectal Metastases Grouped by Site: A Pooled Analysis of the Crystal and OPUS Studies
Authors: C.-H. Köhne, C. Bokemeyer, G. Folprecht, U. Sartorius, M. Schlichting, P. Rougier, E. Van Cutsem
Journal: Annals of Oncology (2012)
A Synthetic Evaluation Of Genetic and Pharmacological Resistance To Clopidogrel and On Treatment Residual Platelet Aggregation In Patients With Atherothrombosis
Authors: Grigoris T Gerotziafas, Severin Bouffard, Patrick Van Dreden, Amir Kartechi, Ilias Evmorfiadis, Marie-Paule Roman, Vassiliki Galea, Dimitra Karipidi, Ismail Elalamy
Journal: Blood (2013)
Combination of 4-Methylumbelliferone and Adenoviral Gene Transfer of Interleukin-12 Reduced the Expression of Cancer Stem Cells Markers, and Showed a Potent Antitumor Effect in an Experimental Hepatocellular Carcinoma Model with Fibrosis
Authors: M.M. Rodriguez, M. Malvicini, E. Fiore, S.G. Bustillo, F. Piccioni, E. Peixoto, C. Atorrasagasti, M. Garcia, L. Alaniz, G. Mazzolini
Journal: Journal of Hepatology (2016)
Safety and Efficacy of Sofosbuvir plus Simeprevir in a Spanish Cohort of 622 Cirrhotic Patients Infected with Genotypes 1 or 4
Authors: Z. Mariño, J.M. Pascasio, G. Sánchez-Antolin, C. Baliellas, M. Prieto, J.M. Moreno, J.A. Carrión, I. Fernández, A. Gomez, J.L. Montero, A. Castro, S. Pascual, J. Cabezas, A. Arencibia C. Del, J.L. Calleja, J.J. Sanchez-Ruano, L. Castells, A. Albillos, M. Romero, J. García-Samaniego, I. Narváez, T. Serrano, A. Giraldez, X. Xiol, V. Hontangas, V. Cuervas-Mons, J. Crespo, X. Forns
Journal: Journal of Hepatology (2016)
University does not have to release copies of contract with Boehringer Ingelheim Foundation, German court rules
Authors: Ned Stafford
Journal: BMJ (2016)

A German court has ruled that the publicly funded Mainz University does not have to release copies of a cooperation contract the university signed with the Boehringer Ingelheim Foundation in return for €150m (£128m; $168m) in donations to fund medical research.

The ruling, issued on 14 September 2016 by the Administrative Court of Mainz, was in response to a lawsuit filed by Christian Kreiss, an advocate of transparency in research funding and professor of financing at Aalen University of Applied Science. Kreiss filed the lawsuit after the university denied his request to make a copy of the contract, which critics have dubbed a “secret contract” that they contend allows the foundation to influence “scientific freedom” at the university.

The …
Stereotactic Ablative Radiotherapy in the Treatment of Hepatocellular Carcinoma Lesions Larger than 3 Centimeters
Authors: M. Diotallevi, P. Carucci, A. Guarneri, E. Trino, D. Campion, P. Franco, S. Mirabella, R. Ragona, S. Gaia, M. Salizzoni, U. Ricardi, M. Rizzetto
Journal: Journal of Hepatology (2016)
Carriers of the ABCB4 PT175A Allele might be At-Risk of Increased Liver Injury: Analysis of Two Independent Cohorts of Patients
Authors: M. Krawczyk, M. Rau, J. Schattenberg, F. Grünhage, H. Bantel, A. Pathil, M. Demir, J. Kluwe, T. Boettler, A. Geier, F. Lammert
Journal: Journal of Hepatology (2016)
The IL10-819C/T is Associated with Major Depressive Disorder in Patients with Chronic Hepatitis C
Authors: L.R. Cunha, D.A. Vieira, Y.G. Giampietro, A.D. Gomes, C. Faria, R. Teixeira, O.A. Martins Filho, F.S. Neves, G.A. Rocha, D.M. Queiroz, L.D. Silva
Journal: Journal of Hepatology (2016)
Lack of NLRP3-Inflammasome Leads to Gut-Liver AXIS Derangement and Increases Hepatic Injury in a Mouse Model of Non-Alcoholic Fatty Liver Disease
Authors: I. Pierantonelli, L. Agostinelli, C. Rychlicki, M. Gaggini, C. Fraumene, E. Mingarelli, C. Saponaro, V. Manghina, E. Buzzigoli, C. Pinto, L. Trozzi, S. Saccomanno, A. Benedetti, M. Marzioni, S. De Minicis, S. Uzzau, A. Gastaldelli, G. Svegliati-Baroni
Journal: Journal of Hepatology (2016)
Efficacy of Tyrosine Kinase Inhibitors in Third Line Therapy in Chronic Phase Chronic Myeloid Leukemia
Authors: Elza Lomaia, Andrey Zaritskey, Vasily Shuvaev, Irina Martynkevich, Mikhail Fominykh, Ekaterina Ovsyannikova, Natalia Lazorko, Natalia Matyuhina, Pavel Butylin, Elena Machyulaitene, Evgenia Salamatova, Kudrat Abdulkadyrov
Journal: Blood (2015)
Liver Derived MIR-122 Mediates Inflammation-Induced Anemia by Targeting Erythropoietin in the Kidney
Authors: M. Rivkin, E. Zorde-Khvalevsky, A. Simerzin, C. Chai, J. Yuval, R. Schneider, M. Heikenwalder, E. Galun, H. Giladi
Journal: Journal of Hepatology (2016)
Role of Circulating Propionate in Portal Hypertension in Cirrhosis
Authors: C. McDougall, A. Davila-Cervantes, P. Tandon, A. Mason, J.J. Lozano, C.Z. Meireles, S. Casu, E. Ruiz, J.C. Garcia-Pagan, J. Bosch, J.G. Abraldes
Journal: Journal of Hepatology (2016)
Evaluation of Published Single-Nucleotide Polymorphisms (SNPs) Associated with Cytomegalovirus Infection and Disease after Hematopoietic Cell Transplantation in a Large Caucasian Cohort
Authors: Sachiko Seo, Wenhong Fan, John A. Hansen, Barry E. Storer, Steven A. Pergam, Margaret L. Green, Sezen Ozkok, Sonia Goyal, Cynthia Fisher, Sangeeta Hingorani, Edus H. Warren, Paul J. Martin, Lue Ping Zhao, Michael Boeckh
Journal: Blood (2014)
A 22-year-old woman with unexplained exertional dyspnoea
Authors: M Internullo, M Bonini, P Marinelli, E Perli, B Cerbelli, P Palange
Journal: Thorax (2016)

A 22-year-old woman was referred to our respiratory outpatient clinic to undergo a cardiopulmonary exercise test (CPET), following presentation with a 2-year history of progressive unexplained exertional dyspnoea (ED).Specifically, she described dyspnoea precipitated by walking or running, which gradually improved with rest.She denied chest pain, cough, asthenia or muscular weakness.Until the age of 20, she practised regular non-competitive physical activity.The patient had at term natural childbirth and normal psychophysical development.Menstrual period, started at the age of 14 years, was regular; no pregnancy, nor miscarriage.She was a lifelong non-smoker with no history of illicit substance use or occupational exposure (university student).Her past history included multinodular euthyroid goitre for which she was prescribed regular levothyroxine (75 μg/100 μg on alternate days).She also reported intermittent gastrointestinal discomfort, which had been ascribed to lactose intolerance for which, however, she was not prescribed a lactose-free diet.Her family history revealed an uncle deceased during childhood for 'cardiac arrhythmia'.Cardiorespiratory and neurological examination was unremarkable.She was normotensive (blood pressure (BP) 100/60 mm Hg, heart rate (HR) 98 bpm in sinus rhythm), not tachypnoeic (respiratory rate 16 breaths/min) and had preserved oxygen saturation (SatO 2 98%).Her body mass index was 19.3.Pulmonary function tests showed normal flow indices (FVC 3.52 L-88% of pred; FEV 1 3.35 L-96% of pred; Tiffeneau index FEV1/FVC 0.95) and preserved lung volumes and gas transfer (total lung capacity 3.94 L-90% of pred; diffusing capacity of the lungs for carbon monoxide, 96% of pred).A high-resolution chest tomography showed no sign of lung disease.Cardiological (including rest, stress and Holter ECG, as well as cardiac ultrasounds) and neurological (including electromyography) exams showed no abnormalities.Routine blood tests (cell count, glucose and electrolyte levels, iron and ferritin profile, lipid screening, kidney and liver function), erythrocyte sedimentation rate, C reactive protein and muscular enzyme (creatine kinase with isoenzymes) values were within normal ranges.Thyroid hormones (measured during replacement therapy) were normal: thyroid-stimulating hormone (TSH) 0.31 mUI/mL, FT 3 2.94 pmol/L, FT 4 13.8 pmol/L.Autoimmune screening, including antinuclear antibodies, extractable nuclear antigens, anti-double
Création d’un protocole d’évaluation de la qualité des données sur la grippe recueillies par les médecins sentinelles en Europe
Authors: J F Aguilera, W J Paget, J Van Der Velden
Journal: Eurosurveillance (2002)

EISS a mis en place un protocole d’evaluation de la qualite des donnees cliniques recueillies par les reseaux sentinelles de surveillance de la grippe. Applique dans trois regions espagnoles et en Belgique, ce protocole a permis de produire des recommandations pour ameliorer la qualites des activites de surveillance.
Fxr Agonism by Gs-9674 Decreases Steatosis and Fibrosis in a Murine Model of Nash
Authors: J.T. Liles, S. Karnik, E. Hambruch, C. Kremoser, M. Birkel, W.J. Watkins, D. Tumas, D. Breckenridge, D. French
Journal: Journal of Hepatology (2016)
Hepatitis C Core Antigen Assay for the Monitoring of Treatment with Direct Antiviral Agents in Patients with Chronic Hepatitis C
Authors: E. Loggi, C. Cursaro, A. Scuteri, R. Vukotic, E. Grandini, M. Margotti, V. Guarneri, M. Stanzani, S. Galli, G. Furlini, C. Galli, M.P. Landini, P. Andreone
Journal: Journal of Hepatology (2016)
Role Of Cytogenetic Abnormalities At Baseline and During 5-Year Follow-Up In Multiple Myeloma Patients Treated On The Total Therapy 3 Protocol
Authors: Sarah Waheed, Jeffrey Sawyer, Adam Rosenthal, Frits van Rhee, Nathan M Petty, Saad Z Usmani, Clyde Bailey, Christoph Heuck, Antje Hoering, Bart Barlogie
Journal: Blood (2013)
Donor Lymphocytes Depleted of Alloreactive T-Cells (ATIR101) Reduce Transplant Related Mortality and Improve Overall Survival in Haploidentical HSCT for Patients with AML and ALL, Using an Immunosuppressant-Free Transplant Regimen
Authors: Denis-Claude Roy, Silvy Lachance, Jean Roy, Irwin Walker, Johan Maertens, Sandra Cohen, Stephen Ronan Foley, Philippe Lewalle, Eduardo Olavarria, Dominik Selleslag, Manfred Rudiger, Jurjen Velthuis, Karen Reitsma, Lisya Gerez, Jeroen Rovers, Halvard Bonig, Stephan Mielke
Journal: Blood (2015)